Five-Year Overall Survival Data and Evidence Context in Metastatic Castration-Sensitive Prostate Cancer

In this segment, Dr. Graham and Dr. Sokolova examine the significance of five-year overall survival data reported in metastatic castration-sensitive prostate cancer and discuss how these results should be interpreted alongside findings from other mCSPC trials. The conversation focuses on what longer-term follow-up reveals about the durability of survival benefit and how mature data help refine expectations around long-term disease control. Dr. Sokolova emphasizes the importance of viewing individual trial results within the broader mCSPC evidence landscape, taking into account differences in study design, patient populations, and treatment strategies. Both experts highlight that cross-trial interpretation requires caution and should inform, rather than dictate, clinical decision-making. Overall, this segment reinforces how long-term survival data contribute to a more comprehensive understanding of treatment outcomes and support nuanced, evidence-based approaches to managing patients with mCSPC.